Sapience Therapeutics Announces Surgical Sub-Study of Ongoing Phase 1-2 Trial of ST101 in Recurrent and Newly Diagnosed GBM Patients
- Monday, August 8, 2022, 7:14
- Business
- Add a comment
-Sub-study is designed to evaluate the safety and tolerability of ST101 as monotherapy in recurrent GBM patients and in combination with radiation ± temozolomide in newly diagnosed patients- – ST101 demonstrated clinical proof-of-concept with a confirmed partial response in a patient with…
About the Author
adminasapcorp has written 41562 stories on this site.